Goldman Sachs
EPRX

Goldman Sachs’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Goldman Sachs’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$384K Sell
53,080
-4,978
-9% -$40.1K ﹤0.01% 5758
2025
Q4 		$438K Buy
58,058
+17,958
+45% +$111K ﹤0.01% 5674
2025
Q3 		$237K Buy
40,100
+300
+0.8% +$1.63K ﹤0.01% 5883
2025
Q2 		$229K Buy
39,800
+5,300
+15% +$20.4K ﹤0.01% 5591
2025
Q1 		$113K Hold
34,500
– – ﹤0.01% 5763
2024
Q4 		$109K Hold
34,500
– – ﹤0.01% 5754
2024
Q3 		$90.7K Buy
+34,500
New +$90.7K ﹤0.01% 5579

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs's EPRX Position: Q1 2026 in Review

Goldman Sachs reduced its Eupraxia Pharmaceuticals (EPRX) stake by 8.6% in Q1 2026, selling an estimated $40.1K and leaving 53,080 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #5758.

Goldman Sachs first reported a position in EPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $438K in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Goldman Sachs held 53,080 shares of Eupraxia Pharmaceuticals worth $384K as of Q1 2026.
  • Goldman Sachs sold 4,978 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $40.1K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5758 holding.
  • Goldman Sachs first reported a position in Eupraxia Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Goldman Sachs's Eupraxia Pharmaceuticals position peaked at $438K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.